Vildagliptin is an oral agent commonly used to help with the management of Type 2 Diabetes Mellitus in adults. The medicine is relevant in conditions associated with acute or disruptive episodes related to blood sugar.

This medication is applied in addressing conditions associated with high blood sugar. It is used when lifestyle modifications alone are insufficient, either as monotherapy or as an add-on agent alongside other oral anti-diabetic medications.

Main Uses and Therapeutic Benefit

Vildagliptin is primarily used for managing Type 2 Diabetes Mellitus, helping to achieve and maintain stability when symptoms create noticeable physiological strain. The core therapeutic focus is on reducing symptoms related to physical discomfort caused by hyperglycemia, a key symptom cluster that helps address manifestations linked to organ-specific functional stress.

“The medication supports a healthier, more consistent balance of blood sugar, which assists with maintaining functional stability when symptoms interfere with routine activities.”

When symptoms intensify, Vildagliptin provides therapeutic support that helps maintain a sense of stability when symptoms are more noticeable, contributing to improved comfort during symptomatic periods.

---

Quick Fact: Support for Hyperglycemia Symptoms Vildagliptin is commonly used to help manage the symptoms related to elevated blood sugar in adult patients with Type 2 Diabetes.

---

Population Eligibility for Vildagliptin

Official regulatory documents define specific patient populations for whom Vildagliptin use is permitted, restricted, or prohibited.

Populations Allowed and Restricted

Population Category	Regulatory Status
Approved Age Group	Adults (18 years and older) with Type 2 Diabetes Mellitus
Older Adults (65+)	Allowed; no dose adjustment necessary based on age alone
Renal Impairment	Restricted use; dosage modification is required for moderate to severe impairment

Contraindications and Exclusions

Vildagliptin must not be used (Contraindicated) in patients with a known hypersensitivity to the active substance or in those with severe hepatic impairment (severe liver disease).

Use is Not Recommended for several groups due to unestablished safety or efficacy profiles:

• Children and Adolescents (under 18 years of age).
• Pregnant and Breastfeeding women.
• Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA), as the medicine is not indicated for these conditions.

Interactions with other medicines and products

Low Potential for Metabolic Interaction

Vildagliptin is officially documented as having a low potential for pharmacokinetic drug interactions because it is not a substrate, inhibitor, or inducer of key Cytochrome P450 (CYP) enzymes (including 3A4/5, 2D6, etc.). Consequently, it is not expected to affect the clearance of many co-administered medicines that rely on these pathways. Official studies confirmed no clinically relevant pharmacokinetic interaction with drugs such as Digoxin, Metformin, Ramipril, Valsartan, or Warfarin.

Pharmacodynamic and Clinical Interaction Risks

Official labeling describes specific pharmacodynamic interactions where the combined effect or risk is modified:

• Increased Hypoglycemia Risk: Co-administration with Sulfonylureas may result in an additive pharmacodynamic effect, leading to an increased risk of hypoglycemia.
• Increased Angioedema Risk: Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors is officially associated with an increased risk of angioedema.

Compromised Efficacy

The glucose-lowering effect of Vildagliptin may be reduced when co-administered with substances known to cause hyperglycemia, including Thiazides, Corticosteroids, Thyroid products, and Sympathomimetics. No specific interaction with food or alcohol is noted for Vildagliptin monotherapy, though alcohol cautions exist for fixed-dose combinations containing Metformin.

Вилдаглиптин действует как селективный ингибитор фермента Дипептидилпептидазы-4 (DPP-4), который является основной молекулярной мишенью в организме. Инактивация этого фермента предотвращает быстрое разрушение и дезактивацию естественных инкретиновых гормонов, таких как GLP-1 и GIP, увеличивая их активную концентрацию в системном кровотоке.

Увеличенное количество активных инкретинов оказывает двойное действие на поджелудочную железу, но только в условиях повышенного уровня глюкозы. Эта стимуляция вызывает усиленную секрецию инсулина бета-клетками и подавляет неадекватное выделение глюкагона альфа-клетками. Это скоординированное, глюкозозависимое регулирование гормонов модулирует гомеостаз глюкозы в ответ на концентрацию субстрата.

В комбинированных препаратах механизм Вилдаглиптина дополняет действие других компонентов (например, Метформина), влияя на динамику глюкозозависимого гормонального ответа и подавлении глюкагона. Это позволяет одновременно воздействовать как на дисфункцию панкреатических клеток, так и на резистентность, что приводит к совместному воздействию на ключевые метаболические процессы.

How Vildagliptin is Used: Official Administration Guidelines

Vildagliptin is an oral anti-hyperglycemic agent used for the management of Type 2 Diabetes Mellitus in adults. There are specific protocols outlining the correct dosing, frequency, and conditions for its administration.

---

Official Route and Dosing

The medication is available as oral tablets and is administered only by mouth. The maximum recommended dose is 100 mg per day, regardless of the specific combination therapy being used.

Dosing Frequency	Total Daily Dose	Notes
Once Daily	50 mg or 100 mg	100 mg often used for monotherapy.
Twice Daily	100 mg (50 mg BID)	Often used in combination with other agents like a sulfonylurea or insulin.

---

Administration and Special Populations

To ensure adherence and convenience, Vildagliptin tablets can be taken with or without food. If a dose is missed, it should be taken as soon as the patient remembers, but the total daily amount must not exceed the maximum of 100 mg. Double dosing to compensate for a missed dose is not permitted.

Dose adjustments are mandatory for certain patient groups. For adults with moderate or severe renal impairment or End-Stage Renal Disease (ESRD), the recommended daily dose is reduced to 50 mg once daily. The medication is generally not recommended for patients with hepatic impairment. Use in children and adolescents under 18 years is not supported by current data and is therefore not recommended. Vildagliptin is intended for long-term, continuous daily use as part of the overall diabetes management protocol.

Recent Clinical Evidence

Clinical research into vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has primarily focused on its use for managing type 2 diabetes mellitus (T2DM). Studies include randomized controlled trials (RCTs) and long-term observational analyses.

---

Efficacy and Glycemic Control

Evidence consistently shows that treatment regimens involving vildagliptin are associated with reductions in key markers of glucose control, including glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG).

• Monotherapy: Studies in newly diagnosed patients or those unable to tolerate metformin have demonstrated an effect on lowering HbA1c levels.
• Combination Therapy: Vildagliptin has been evaluated as an add-on treatment when T2DM is inadequately controlled by other medications, such as metformin, sulfonylureas, or insulin. These studies suggest that its addition may contribute to improved glycemic outcomes.

Primary Efficacy Findings
Reduction in HbA1c levels
Reduction in Fasting Plasma Glucose (FPG)
Improvements in beta-cell function markers

---

Safety and Tolerability Profile

The overall tolerability profile of vildagliptin across large clinical trials and real-world data has generally been similar to placebo. A notable finding across multiple studies is the low risk of hypoglycemia when used as monotherapy or in combination, particularly compared to certain other classes of glucose-lowering agents.

Studies also observe that vildagliptin is generally considered weight-neutral, meaning it does not typically lead to weight gain. Rare adverse events, such as mild to moderate elevations in liver enzymes or reports of acute pancreatitis, have been documented; these often resolved upon discontinuation of the drug. The absence of an increased risk for major adverse cardiovascular events has also been investigated and generally confirmed in long-term safety studies.

Key Studies & References

1. Vildagliptin in Ventricular Dysfunction Diabetes - VIVIDD
2. Efficacy and safety of vildagliptin combined with metformin in the treatment of type 2 diabetes mellitus: a systematic review

Common questions about Вилдаглиптин (FAQ)

---

Q: What is the onset of action for Vildagliptin? How quickly will my blood sugar drop?

Vildagliptin is known to be rapidly absorbed, with peak plasma concentrations occurring within approximately two hours after dosing. Its action involves rapid and strong inhibition of the DPP-4 enzyme activity. While this mechanism begins quickly, the full therapeutic effect on key long-term glucose control markers, such as HbA1c, is typically observed in clinical studies after approximately 12 to 24 weeks of continuous treatment.

---

Q: Does Vildagliptin cause skin reactions, such as blistering or rashes?

Official product information documents report bullous and exfoliative skin lesions (severe blistering or peeling skin) from post-marketing surveillance, classified as reactions of unknown frequency. The labeling includes a statement that monitoring for skin disorders, such as blistering or ulceration, is recommended during treatment, particularly for patients with pre-existing diabetic skin complications. Rare cases of angioedema (swelling beneath the skin) have also been reported.

---

Q: Does Vildagliptin interact with a specific drug class that requires a dose change?

Official product information notes an increased risk of low blood sugar (hypoglycemia) when Vildagliptin is used along with a sulfonylurea class of medication. This combination is noted as an interaction risk that may require clinical management. Additionally, an increased risk of angioedema is officially reported when Vildagliptin is taken at the same time as ACE-inhibitors (a class of blood pressure medications).

---

Q: Is it safe to use Vildagliptin if I am pregnant or breastfeeding?

Official documents describe Vildagliptin as generally not recommended for use during pregnancy due to the lack of sufficient human safety data. Use is also not recommended while breast-feeding because it is unknown whether the medicine is secreted into human milk, although animal studies have suggested this possibility.

---

Q: Are there any inactive ingredients (excipients) in the tablet that I should be aware of?

Official regulatory information identifies that Vildagliptin tablets contain the inactive ingredient lactose. Because of this, the medicine is not indicated for individuals with rare hereditary problems concerning the handling of certain sugars, specifically galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Official Vildagliptin Storage and Disposal Rules

Official regulatory guidelines for Vildagliptin focus on protecting the medication from environmental factors and ensuring household safety. Storage does not require special temperature conditions, such as refrigeration or specific heat limits. The mandatory requirement is to store the tablets in their original packaging (e.g., blister or container) to protect them from moisture, which is essential for maintaining product stability throughout its shelf life. For household safety, the medicine must be kept out of the sight and reach of children.

Regarding disposal, unused or expired Vildagliptin must not be discarded in wastewater (e.g., flushed down the toilet) or household trash. Disposal must instead follow local requirements for pharmaceutical returns or collections to protect the environment.